$12.08
1.34% day before yesterday
NYSE, Dec 24, 07:00 pm CET
ISIN
US29082K1051
Symbol
EMBC

Embecta Stock price

$12.08
-2.56 17.49% 1M
+1.86 18.20% 6M
-8.57 41.50% YTD
-8.20 40.43% 1Y
-15.44 56.10% 3Y
-34.92 74.30% 5Y
-34.92 74.30% 10Y
-34.92 74.30% 20Y
NYSE, Closing price Wed, Dec 24 2025
+0.16 1.34%

Key metrics

Basic
Market capitalization
$715.3m
Enterprise Value
$1.9b
Net debt
$1.2b
Cash
$225.5m
Shares outstanding
58.5m
Valuation (TTM | estimate)
P/E
7.5 | 4.1
P/S
0.7 | 0.6
EV/Sales
1.8 | 1.7
EV/FCF
10.5
P/B
negative
Dividends
DPS
$0.60
Yield 1Y | 5Y
5.0% | 1.9%
Growth 1Y | 5Y
0.0% | -
Payout 1Y | 3Y
37.0% | 43.1%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$1.1b | $1.1b
EBITDA
$370.2m | $398.8m
EBIT
$329.5m | $330.5m
Net Income
$95.4m | $173.6m
Free Cash Flow
$182.4m
Growth (TTM | estimate)
Revenue
-3.8% | 2.2%
EBITDA
42.8% | 7.8%
EBIT
47.6% | 0.4%
Net Income
21.2% | 82.0%
Free Cash Flow
812.0%
Margin (TTM | estimate)
Gross
63.9%
EBITDA
34.3% | 36.1%
EBIT
30.5%
Net
8.8% | 15.7%
Free Cash Flow
16.9%
Financial Health
Equity Ratio
-59.6%
Return on Equity
-14.7%
ROCE
39.7%
ROIC
30.1%
Debt/Equity
-2.2
More
EPS
$1.6
FCF per Share
$3.1
Short interest
6.8%
Employees
2k
Rev per Employee
$510.0k
Show more

Is Embecta a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Embecta Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Embecta forecast:

1x Buy
11%
4x Hold
44%
4x Sell
44%

Analyst Opinions

9 Analysts have issued a Embecta forecast:

Buy
11%
Hold
44%
Sell
44%

Financial data from Embecta

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
1,080 1,080
4% 4%
100%
- Direct Costs 391 391
1% 1%
36%
690 690
6% 6%
64%
- Selling and Administrative Expenses 332 332
9% 9%
31%
- Research and Development Expense 22 22
73% 73%
2%
370 370
43% 43%
34%
- Depreciation and Amortization 41 41
13% 13%
4%
EBIT (Operating Income) EBIT 330 330
48% 48%
30%
Net Profit 95 95
21% 21%
9%

In millions USD.

Don't miss a Thing! We will send you all news about Embecta directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Embecta Stock News

Neutral
GlobeNewsWire
7 days ago
PARSIPPANY, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the J.P.
Negative
Seeking Alpha
27 days ago
Embecta Corp. (EMBC) faces a challenging fiscal 2026, with flat revenue and earnings growth expected - after a strong fiscal 2025. EMBC's weak outlook is driven by cannula costs, modest volume declines, and higher R&D expenses, despite improved margins and debt reduction. The dividend yield of 4.77% may appeal to income investors, but near-term growth prospects remain limited, warranting a Hold...
Positive
Seeking Alpha
30 days ago
The S&P 600 Small/MidCap index offers high-yield dividend opportunities, with 33 out of 53 top-yielding stocks meeting both the 'safer' and IDEAL dividend Dogcatcher criteria. Top ten S&P600 dividend 'dogs' are projected to deliver 24% to 93% net gains by November 2026, based on analyst targets and current yields. Stocks like KNTK, SM, CRGY, and DEI stand out for strong total return potential, ...
More Embecta News

Company Profile

Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.

Head office United States
CEO Devdatt Kurdikar
Employees 2,100
Founded 1924
Website www.embecta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today